cis-trismethoxy Resveratrol
(Synonyms: 顺式白藜芦醇三甲醚,cis-Trimethoxy Stilbene) 目录号 : GC12352Potent antineoplastic agent
Cas No.:94608-23-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 4 microM for tubulin polymerization
cis-trismethoxy Resveratrol is an anti-mitotic drug.
A mitotic inhibitor is a drug inhibiting mitosis or cell division. Mitotic inhibitors are widely used in cancer treatment, because cancer cells can grow and eventually spread through the body via continuous mitotic division.
In vitro: cis-trismethoxy Resveratrol at 0.3 microM could exert a 80% growth inhibition of human colon cancer Caco-2 cells and arrest growth completely at 0.4 microM. The cis conformation of cis-trismethoxy Resveratrol was also 100-fold more potent than the trans isomer. cis-trismethoxy Resveratrol was able to cause cell cycle arrest at the G2/M phase transition and inhibit tubulin polymerization dose-dependently, leading to the depletion of the polyamines, putrescine and spermidine. In addition, cis-trismethoxy Resveratrol inhibited partially colchicine binding to its binding site on tubulin [1].
In vivo: Previous study found that from the angle of pharmacokinetics, cis-trismethoxy Resveratrol appeared to be a superior analog of resveratrol since it was orally available and showed greater plasma exposure, longer elimination half-life and lower clearance. Due to the superior pharmacokinetic characteristics of cis-trismethoxy Resveratrol had, its potentials as a preventive or therapeutic agent in resveratrol-effective diseases would be considered [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Schneider, Y. ,Chabert, P.,Stutzmann, J., et al. Resveratrol analog (Z)-3,5,4'-trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization. International Journal of Cancer 107, 189-196 (2003).
[2] Lin, H. S. and Ho, P.C. A rapid HPLC method for the quantification of 3,5,4'-trimethoxy-trans-stilbene (TMS) in rat plasma and its application in pharmacokinetic study. Journal of Pharmaceutical & Biomedical Analysis 49, 387-392 (2009).
| Cas No. | 94608-23-8 | SDF | |
| 别名 | 顺式白藜芦醇三甲醚,cis-Trimethoxy Stilbene | ||
| 化学名 | 1,3-dimethoxy-5-[(1Z)-2-(4-methoxyphenyl)ethenyl]-benzene | ||
| Canonical SMILES | COC1=CC(/C=C\C2=CC=C(OC)C=C2)=CC(OC)=C1 | ||
| 分子式 | C17H18O3 | 分子量 | 270.3 |
| 溶解度 | ≤50mg/ml in DMSO;50mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6996 mL | 18.498 mL | 36.9959 mL |
| 5 mM | 0.7399 mL | 3.6996 mL | 7.3992 mL |
| 10 mM | 0.37 mL | 1.8498 mL | 3.6996 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet